Keywords

anxiety, atrial fibrillation, depression, quality of life, recurrence

Authors

1. Koleck, Theresa A. PhD, RN
2. Mitha, Shazia A. MS, RN
3. Biviano, Angelo MD, MPH
4. Caceres, Billy A. PhD, RN, AGPCNP-BC
5. Corwin, Elizabeth J. PhD, RN, FAAN
6. Goldenthal, Isaac MS
7. Creber, Ruth Masterson PhD, MPH, RN, FAHA
8. Turchioe, Meghan Reading PhD, MPH, RN
9. Hickey, Kathleen T. EdD, FNP-BC, ANP-BC, FAHA, FAAN
10. Bakken, Suzanne PhD, RN, FAAN, FACMI

Abstract

Background: Depression and anxiety in patients with atrial fibrillation (AF) and/or atrial flutter may influence the effectiveness of cardioversion and ablation. There is a lack of knowledge related to depressive symptoms and anxiety at the time of these procedures.

Objective: We aimed to describe the prevalence and explore potential covariates of depressive symptoms and anxiety in patients with AF at the time of cardioversion or ablation. We further explored the influence of depressive symptoms and anxiety on quality of life at the time of procedure and 6-month AF recurrence.

Methods: Depressive symptoms, anxiety, and quality of life were collected at the time of cardioversion or ablation using the Patient Health Questionnaire-9, State-Trait Anxiety Inventory, and Atrial Fibrillation Effect on Quality of Life questionnaire. Presence of AF recurrence within 6 months post procedure was evaluated.

Results: Participants (N = 171) had a mean (SD) age of 61.20 (11.23) years and were primarily male (80.1%) and white, non-Hispanic (81.4%). Moderate to severe depressive symptoms (17.2%) and clinically significant state (30.2%) and trait (23.6%) anxiety were reported. Mood/anxiety disorder diagnosis was associated with all 3 symptoms. Atrial fibrillation symptom severity was associated with both depressive symptoms and trait anxiety. Heart failure diagnosis and digoxin use were also associated with depressive symptoms. Trends toward significance between state and trait anxiety and participant race/ethnicity as well as depressive symptoms and body mass index were observed. Study findings support associations between symptoms and quality of life, but not 6-month AF recurrence.

Conclusion: Depressive symptoms and anxiety are common in patients with AF. Healthcare providers should monitor patients with AF for depressive symptoms and anxiety at the time of procedures and intervene when indicated. Additional investigations on assessment, prediction, treatment, and outcome of depressive symptoms and anxiety in patients with AF are warranted.